[{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Targeted Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Onternabez","moa":"CNR","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetra BioPharma \/ Targeted Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioPharma \/ Targeted Pharmaceuticals"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"CNR1","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Anesthesia Research Group UA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Anesthesia Research Group UA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anesthesia Research Group UA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anesthesia Research Group UA \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"101 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"101-PGC-005","moa":"Glucocorticoid receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"101 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"101 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"101 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aspen API","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspen API \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen API \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"TFS Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ TFS Health Science","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ TFS Health Science"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"Aji Bio Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Expanded Collaboration","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Aji Bio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aji Bio Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Aji Bio Pharma \/ Humanigen"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avid Bioservices \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Avid Bioservices \/ Humanigen"},{"orgOrder":0,"company":"Humanigen","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Hercules Capital"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Eversana","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eversana \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Humanigen"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Humanigen"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Enzychem Lifesciences Corporation \/ National Institutes of Health"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Mitem Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma"},{"orgOrder":0,"company":"CNX Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Dexrazoxane","moa":"Iron | DNA topoisomerase II","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"CNX Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNX Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"CNX Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"POLB 001","moa":"MAPK\/p38","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poolbeg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rising Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"Metal ion","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Rising Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rising Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rising Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Ohara Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"BTG Specialty Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"Biomedical Advanced Research and Development Authority","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Biomedical Advanced Research and Development Authority","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedical Advanced Research and Development Authority \/ Rho Inc","highestDevelopmentStatusID":"6","companyTruncated":"Biomedical Advanced Research and Development Authority \/ Rho Inc"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Kindeva Drug Delivery \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"Somatostatin receptor 2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paltusotine","moa":"Somatostatin receptor 2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Duke University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FSD-F2R6-A-CP","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment"},{"orgOrder":0,"company":"SRI International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Undisclosed"},{"orgOrder":0,"company":"SRI International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Undisclosed"},{"orgOrder":0,"company":"HOPO Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"HOPO Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"HOPO Therapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"HOPO Therapeutics \/ BARDA"},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Human Ipsc-Derived Cardiac Tissues","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSurface Biomedical \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ National Institutes of Health"},{"orgOrder":0,"company":"Cultech Ltd","sponsor":"Comac Medical","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LAB4","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Cultech Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cultech Ltd \/ Comac Medical","highestDevelopmentStatusID":"1","companyTruncated":"Cultech Ltd \/ Comac Medical"},{"orgOrder":0,"company":"Novozymes","sponsor":"Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center"},{"orgOrder":0,"company":"Novozymes","sponsor":"Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc"},{"orgOrder":0,"company":"University Hospital Center of Martinique","sponsor":"BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"University Hospital Center of Martinique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital Center of Martinique \/ BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Center of Martinique \/ BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ricin Toxin","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ricin Toxin Vaccine","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SYHX1901","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Therapeutic Plasma Exchange","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Heart Health Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Heart Health Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heart Health Research Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Heart Health Research Center \/ AstraZeneca"},{"orgOrder":0,"company":"Erdal","sponsor":"ActoPharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Erdal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erdal \/ ActoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Erdal \/ ActoPharma"},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Persavita \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Undisclosed"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ Jubilant Therapeutics"}]
Find Pharmacology/Toxicology Clinical Drug Pipeline Developments & Deals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Aspen API. More than just an API™
